Long QT syndrome with syncope: management when initial therapy is not sufficient
Patients with congenital long QT syndrome who experience syncope (fainting) prior to medical treatment represent a symptomatic, higher-risk presentation. When initial therapy does not achieve its target, a defined next-line approach is warranted.
Clinical scenario
Long QT syndrome with syncope (fainting) prior to medical treatment — a symptomatic presentation in which active management is required.
Previous treatment & escalation trigger
When initial therapy was not enough
Initial management — comprising general recommendations (avoiding QT-prolonging drugs, correcting electrolyte abnormalities, avoiding genotype-specific arrhythmia triggers) together with a non-selective beta-blocker, and with mexiletine added where genotype-indicated — was insufficient when the QTc interval did not shorten sufficiently on mexiletine testing, or the patient remained symptomatic on treatment. This protocol applies in that escalation setting.
Next-line approach (partial overview)
Treatment direction
When a patient with LQTS remains symptomatic while receiving beta-blockers and genotype-specific therapies, the next step involves a device-based or interventional cardiac procedure. A distinct interventional alternative exists for cases where the primary option is contraindicated or declined.
The complete indications, sequencing, and criteria for each option are available in the full protocol.
References
DOI: 10.1093/eurheartj/ehac262
- Syncope prior to medical treatment.
- ICD implantation is recommended in patients with LQTS who are symptomatic while receiving beta-blockers and genotype-specific therapies.
- LCSD is indicated in patients with symptomatic LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-specific drugs with an ICD and experiences multiple shocks or syncope due to VA.
- Either ICD implantation or LCSD should be considered in patients with symptomatic LQTS, when beta-blockers and genotype-specific therapies are not tolerated or contraindicated at the therapeutic dose.
View source ↗